SCHEMBL7419489

SCHEMBL7419489

CC(C)(C)c1ccc(S(=O)(=O)NCC(NS(=O)(=O)c2ccc(C(C)(C)C)cc2)C(=O)NO)cc1

nearest known ligand 0.77

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MMP7 P09237 5/20 0.77
MMP9 P14780 3/20 0.77
MMP10 P09238 1/20 0.77
ALDH1A1 P00352 3/20 0.55
MAPT P10636 2/20 0.55
HDAC3 O15379 3/20 0.53
HDAC8 Q9BY41 3/20 0.53
HDAC6 Q9UBN7 3/20 0.53
HDAC11 Q96DB2 2/20 0.50
SLC1A2 P43004 1/20 0.49
MMP2 P08253 2/20 0.48
EEF2K O00418 1/20 0.46
MMP1 P03956 1/20 0.46
MMP14 P50281 1/20 0.46
ADAM17 P78536 1/20 0.46
HDAC1 Q13547 1/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
UQCRB P14927 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7414393 0.95 MMP7 (0.70) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7417364 0.94 MMP7 (0.69) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7417547 0.94 MMP7 (0.69) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7414877 0.92 MMP7 (0.66) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7415839 0.92 MMP7 (0.66) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7416539 0.89 MMP7 (0.61) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7412866 0.89 MMP7 (0.61) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7411422 0.86 MMP7 (0.58) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7417174 0.86 MMP7 (0.58) MMP7MMP9MMP10ALDH1A1MAPT
SCHEMBL7417214 0.86 MMP7 (0.61) MMP7MMP9MMP10ALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6218389-B1 FOR THERAPY AND PROPHYLAXIS OF ARTHRITIS, CANCER, CARDIOVASCULAR DISORDERS; SKIN DISORDERS; OCULAR DISORDERS; INFLAMMATION AND GUM DISEASES, MULTIPLE SCLEROSIS, CACHEXIA, PREVENTING LOOSENING OF PROSTHETIC DEVICES THE PROCTER & GAMBLE CO. 2001-04-17 US disclosed
EP-1009737-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 2000-06-21 EP disclosed
WO-1999006340-A2 SULFONYLAMINO SUBSTITUTED HYDROXAMIC ACID DERIVATIVES AS METALLOPROTEASE INHIBITORS THE PROCTER & GAMBLE COMPANY (US) 1999-02-11 WO disclosed